Current Diabetes Reports

, 18:123 | Cite as

App-Based Insulin Calculators: Current and Future State

  • Leslie Eiland
  • Meghan McLarney
  • Thiyagarajan Thangavelu
  • Andjela DrincicEmail author
Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Health Care Delivery Systems and Implementation in Diabetes


Purpose of Review

To perform a comprehensive literature review and critical assessment of peer-reviewed manuscripts addressing the efficacy, safety, or usability of insulin calculator apps.

Recent Findings

Managing diabetes with insulin can be complex, and literacy and numeracy skills pose barriers to manual insulin dose calculations. App-based insulin calculators are promising tools to help people with diabetes administer insulin safely and have potential to improve glycemic control. While a large number of apps which assist with insulin dosing are available, there is limited data evaluating their efficacy, safety, and usability. Recently, a need for regulatory oversight has been recognized, but few apps meet federal standards. Thus, choosing an appropriate app is challenging for both patients and providers. An electronic literature review was performed to identify insulin calculator apps with either evidence for efficacy, safety or usability published in peer-reviewed literature or with FDA/CE approval. Twenty apps were identified intended for use by patients with diabetes on insulin. Of these, nine included insulin calculators. Summaries of each app, including pros and cons, are provided.


Insulin-calculator apps have the potential to improve self-management of diabetes. While current literature demonstrates improvements in quality of life and glycemic control after use of these programs, larger trials are needed to collect outcome and safety data. Also, further human factor analysis is needed to assure these apps will be adopted appropriately by people with diabetes. App features including efficacy and safety data need to be easily available for consumer review and decision making. Higher standards need to be set for app developers to ensure safety and efficacy.


Smartphone applications Insulin bolus calculators Type 1 diabetes Type 2 diabetes FDA 


Compliance with Ethical Standards

Conflict of Interest

Leslie Eiland, Meghan McLarney, Thiyagarajan Thangavelu, and Andjela Drincic declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21. Scholar
  2. 2.
    Centers for Disease Control and Prevention: Diabetes Public Health Resource. 2012. Accessed 13 August 2018.
  3. 3.
    American Diabetes Association. 4. Lifestyle management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S38–50. Scholar
  4. 4.
    Cavanaugh K, Huizinga MM, Wallston KA, Gebretsadik T, Shintani A, Davis D, et al. Association of numeracy and diabetes control. Ann Intern Med. 2008;148:737–46.CrossRefGoogle Scholar
  5. 5.
    Huizinga MM, Carlisle AJ, Cavanaugh KL, Davis DL, Gregory RP, Schlundt DG, et al. Literacy, numeracy, and portion-size estimation skills. Am J Prev Med. 2009;36:324–8. Scholar
  6. 6.
    Osborn CY, Cavanaugh K, Wallston KA, Rothman RL. Self-efficacy links health literacy and numeracy to glycemic control. J Health Commun. 2010;15(Suppl 2):146–58. Scholar
  7. 7.
    Sussman A, Taylor EJ, Patel M, Ward J, Alva S, Lawrence A, et al. Performance of a glucose meter with a built-in automated bolus calculator versus manual bolus calculation in insulin-using subjects. J Diabetes Sci Technol. 2012;6:339–44. Scholar
  8. 8.
    Klonoff DC. The current status of mHealth for diabetes: will it be the next big thing? J Diabetes Sci Technol. 2013;7:749–58. Scholar
  9. 9.
    • Hirsch IB, Parkin CG. Unknown safety and efficacy of smartphone bolus calculator apps puts patients at risk for severe adverse outcomes. J Diabetes Sci Technol. 2016;10:977–80. This article discusses the challenges that patients on MDI therapy face when manually calculating bolus insulin doses. While insulin calculator apps are a promising way to addresses these issues, there are also many concerns about the safety and efficacy of currently-available apps. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    • Huckvale K, Adomaviciute S, Prieto JT, Leow MK, Car J. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015;13:106–015–314-7. This article provides a thorough assessment of English-language rapid acting insulin dose calculators, and points out the many issues with safety and accuracy that HCPs need to be aware of prior to recommending an app to their patients. CrossRefGoogle Scholar
  11. 11.
    Shuren J, Patel B, Gottlieb S. FDA regulation of mobile medical apps. JAMA. 2018;320:337–8. Scholar
  12. 12.
    U.S. Food & Drug Administration: International Medical Device Regulators Forum (IMDRF). 2008. Accessed 13 August 2018.
  13. 13.
    Drincic A, Prahalad P, Greenwood D, Klonoff DC. Evidence-based mobile medical applications in diabetes. Endocrinol Metab Clin N Am. 2016;45:943–65.CrossRefGoogle Scholar
  14. 14.
    Sun C, Malcolm JC, Wong B, Shorr R, Doyle MA. Improving glycemic control in adults and children with type 1 diabetes with the use of smartphone-based Mobile applications: a systematic review. Can J Diabetes. 2018.Google Scholar
  15. 15.
    Hou C, Carter B, Hewitt J, Francisa T, Mayor S. Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials. Diabetes Care. 2016;39:2089–95.CrossRefGoogle Scholar
  16. 16.
    • Veazie S, Winchell K, Gilbert J, Paynter R, Ivlev I, Eden KB, Nussbaum K, Weiskopf N, Guise JM, Helfand M. Rapid evidence review of mobile applications for self-management of diabetes. J Gen Intern Med. 2018; This study provides a thorough review of apps currently available for people with Type 1 and Type 2 diabetes that have evidence available in the literature. CrossRefGoogle Scholar
  17. 17.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. Scholar
  18. 18.
    Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013;36:3613–9. Scholar
  19. 19.
    Mora P, Buskirk A, Lyden M, Parkin CG, Borsa L, Petersen B. Use of a novel, remotely connected diabetes management system is associated with increased treatment satisfaction, reduced diabetes distress, and improved glycemic control in individuals with insulin-treated diabetes: first results from the personal diabetes management study. Diabetes Technol Ther. 2017;19:715–22. Scholar
  20. 20.
    Drion I, Pameijer LR, van Dijk PR, Groenier KH, Kleefstra N, Bilo HJ. The effects of a mobile phone application on quality of life in patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Sci Technol. 2015;9:1086–91. Scholar
  21. 21.
    Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, et al. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 study). Diabetes Care. 2011;34:533–9. Scholar
  22. 22.
    Skrovseth SO, Arsand E, Godtliebsen F, Joakimsen RM. Data-driven personalized feedback to patients with type 1 diabetes: a randomized trial. Diabetes Technol Ther. 2015;17:482–9. Scholar
  23. 23.
    Bergenstal RM, Bashan E, McShane M, Johnson M, Hodish I. Can a tool that automates insulin titration be a key to diabetes management? Diabetes Technol Ther. 2012;14:675–82. Scholar
  24. 24.
    Rossi MC, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: a new telemedicine system enabling flexible diet and insulin therapy while improving quality of life: an open-label, international, multicenter, randomized study. Diabetes Care. 2010;33:109–15. Scholar
  25. 25.
    Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, et al. Impact of the “Diabetes Interactive Diary” telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. Diabetes Technol Ther. 2013;15:670–9. Scholar
  26. 26.
    Garg SK, Shah VN, Akturk HK, Beatson C, Snell-Bergeon JK. Role of mobile technology to improve diabetes care in adults with type 1 diabetes: the Remote-T1D Study iBGStar((R)) in type 1 diabetes management. Diabetes Ther. 2017;8:811–9. Scholar
  27. 27.
    Niel JV, Geelhoed-Duijvestijn PH, on behalf of the Dutch Insulinx Study Group. Use of a smart glucose monitoring system to guide insulin dosing in patients with diabetes in regular clinical practice. J Diabetes Sci Technol. 2014;8:188–9.CrossRefGoogle Scholar
  28. 28.
    Clements MA, Staggs VS. A mobile app for synchronizing glucometer data: impact on adherence and glycemic control among youths with type 1 diabetes in routine care. J Diabetes Sci Technol. 2017;11:461–7. Scholar
  29. 29.
    Kirwan M, Vandelanotte C, Fenning A, Duncan MJ. Diabetes self-management smartphone application for adults with type 1 diabetes: randomized controlled trial. J Med Internet Res. 2013;15:e235. Scholar
  30. 30.
    Bailey TS, Stone JY. A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice. Expert Opin Drug Deliv. 2017;14:697–703. Scholar
  31. 31.
    Pfutzner A, Stratmann B, Funke K, Pohlmeier H, Rose L, Sieber J, et al. Real-world data collection regarding titration algorithms for insulin glargine in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2016;10:1122–9. Scholar
  32. 32.
    Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract. 2016;22:84–113. Scholar
  33. 33.
    Knight BA, McIntyre HD, Hickman IJ, Noud M. Qualitative assessment of user experiences of a novel smart phone application designed to support flexible intensive insulin therapy in type 1 diabetes. BMC Med Inform Decis Mak. 2016;16:119–016–0356-6. Scholar
  34. 34.
    Mazurczak K, Pankowska E, Ladyzynski P, Foltynski P. The first use of bolus calculator with speech analyzer. J Diabetes Sci Technol. 2017;11:7–11. Scholar
  35. 35.
    Foltynski P, Ladyzynski P, Pankowska E, Mazurczak K. Efficacy of automatic bolus calculator with automatic speech recognition in patients with type 1 diabetes: a randomized cross-over trial. J Diabetes. 2018;10:600–8. Scholar
  36. 36.
    Ladyzynski P, Krzymien J, Foltynski P, Rachuta M, Bonalska B. Accuracy of automatic carbohydrate, protein, fat and calorie counting based on voice descriptions of meals in people with type 1 diabetes. Nutrients. 2018;10: CrossRefGoogle Scholar
  37. 37.
    Accueil | Diabeo®. 2018. Accessed 14 August 2018.
  38. 38.
    DID Plus - Diabetes Interactive Diary - Meteda. 2018. Accessed 14 August 2018.
  39. 39.
    Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–8.CrossRefGoogle Scholar
  40. 40.
    Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23:736–42.CrossRefGoogle Scholar
  41. 41.
    Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62. Scholar
  42. 42.
    Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902–13.CrossRefGoogle Scholar
  43. 43.
    Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858–64. Scholar
  44. 44.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.CrossRefGoogle Scholar
  45. 45.
    Meade LT, Rushton WE. Accuracy of carbohydrate counting in adults. Clin Diabetes. 2016;34:142–7. Scholar
  46. 46.
    Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015;38:1008–15. Scholar
  47. 47.
    Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14:16–22. Scholar
  48. 48.
    SNAPCARBS. 2018. Accessed 14 August 2018.
  49. 49.
    Pankowska E, Ladyzynski P, Foltynski P, Mazurczak K. A randomized controlled study of an insulin dosing application that uses recognition and meal bolus estimations. J Diabetes Sci Technol. 2017;11:43–9. Scholar
  50. 50.
    Food and Drug Administration (FDA): Medical Devices - Cybersecurity. 2018. Accessed 14 August 2018.
  51. 51.
    Rapid Calc: A small revolution in diabetes management. Accessed 14 August 2018.
  52. 52.
    Boyle L, Grainger R, Hall RM, Krebs JD. Use of and beliefs about mobile phone apps for diabetes self-management: surveys of people in a hospital diabetes clinic and diabetes health professionals in New Zealand. JMIR Mhealth Uhealth. 2017;5:e85. Scholar
  53. 53.
    Jordan P, Thomas B, Weerdmeester B, McClelland I. Usability Evaluation In Industry. 1996.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Leslie Eiland
    • 1
  • Meghan McLarney
    • 2
  • Thiyagarajan Thangavelu
    • 1
  • Andjela Drincic
    • 1
    Email author
  1. 1.Division of Diabetes, Endocrinology & MetabolismUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Nebraska Medicine – Diabetes CenterUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations